TRAMmoniTTR Study Genetic Screening of an At-risk Population for hATTR and Monitoring of TTR Positive Subjects

CENTOGENE

Status: Completed

Conditions: Transthyretin Amyloidosis; Polyneuropathies; Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy; Transthyretin-Related (ATTR) Familial Amyloid Polyneuropathy; Cardiomyopathies

Study type: Observational

Funder types: Industry

Identifiers

NCT03237494

TRAM2 analysis

Details and patient eligibility

About

National, multicenter, epidemiological, longitudinal protocol to investigate the hATTR prevalence in an at-risk population for Hereditary Transthyretin Amyloidosis (hATTR) and subjects diagnosed with hATTR, to monitor the clinical status in TTR positive subjects and to establish hATTR biomarker/s

Full description

Hereditary TransThyRetin Amyloidosis (hATTR) is a slowly progressive condition, that is transmitted as an autosomal dominant trait and is characterized by abnormal extracellular deposits of fibrillar, misfolded proteins (amyloid fibrils) in the body. Amyloid fibrils can be deposited in different body compartments, such as the nerves, heart, gastrointestinal tract, kidneys and brain, causing severe structural changes. More than 30 proteins can trigger the formation of amyloid fibrils, 5 of which can infiltrate the heart and cause cardiac amyloidosis.

One of these amyloidogenic protein is transthyretin, formerly known as prealbumin. Transthyretin (TTR) is found primarily in the serum (secreted by the liver) and cerebrospinal fluid (secreted by the choroid plexus) and functions as a carrier for the hormone thyroxine (T4) and retinol-binding protein (bound to retinol or vitamin A). The destabilization of the TTR protein and the formation of misfolded TTR.

It is the goal of this study to investigate the prevalence of Hereditary Transthyretin-related Amyloidosis (hATTR) in a cohort of 5.000 subjects are at risk for Hereditary Transthyretin Amyloidosis (hATTR) and subjects diagnosed with hATTR, to monitor the clinical status in TTR positive subjects and to establish hATTR biomarker/s.

Enrollment: 5,028 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Informed consent is obtained from the participant
• The participant is 18 years of age or older
• The participant has no diagnosis of alcoholism according to international guidelines
• The participant has not undergone chemotherapy for any carcinoma

AND

The participant is at risk for hATTR due to two or more the factors listed below:

• cardiomyopathy or polyneuropathy with no obvious etiology atypical Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) or Motor Neuron Disease (MND)
• autonomic dysfunction
• hypertrophic cardiomyopathy or heart failure with preserved ejection fraction Left Ventricular Hypertrophy (LVH)
• bilateral carpal tunnel syndrome
• spinal stenosis or spinal radiculopathy
• gait disorders
• ocular changes involving vitreous opacities
• unexplained weight loss >5kg
• renal abnormalities
• family history of hATTR
• based on imaging or biopsy suspected for the wild type TTR (ATTR) and not genetically tested for hATTR

OR • The participant is diagnosed with hATTR

OR

• The participant is a 1st or 2nd degree relative of the TTR positive subject

Exclusion Criteria

• Informed consent is not obtained from the participant
• The participant is younger than 18 years of age
• The participant has a diagnosis of alcoholism according to International guidelines
• The participant has undergone chemotherapy for any carcinoma
• The participant is not at risk for hATTR

Trial design

5,028 participants in 1 patient group

Participants at risk for hATTR and participants diagnosed with hATTR

Description:

Participants 18 years of age or older